This animated video summarizes a network meta-analysis of randomized clinical trials comparing the effects of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality in patients with type 2 diabetes. Read the article at: https://ja.ma/2H8FpIo.
Key Points:
Question: How do sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors compare in reducing mortality and cardiovascular events in patients with type 2 diabetes?
Findings: In this network meta-analysis that includes 236 trials with 176 310 participants, the use of SGLT-2 inhibitors or GLP-1 agonists was significantly associated with lower all-cause mortality compared with the control groups (placebo or no treatment) (hazard ratio [HR], 0.80, and HR, 0.88, respectively) and with DPP-4 inhibitors (HR, 0.78, and HR, 0.86, respectively).
Meaning: In patients with type 2 diabetes, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with better mortality outcomes than DPP-4 inhibitors.
Video Rating: / 5
You forget to name medicines falls in these three catigory.
JAMA really should be proposing fasting versus another set of toxic drugs.
Cómo adquirir ese meficamento
…or eat what you evolved to eat and get the same benefits with no side effects.